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Abstract 
We describe a case of a 60-year old male who developed an acute prosthetic joint infection (PJI) of 
the knee, secondary to erysipelas of the lower leg due to beta-hemolytic Group G streptococci. As 
it is unknown how often this phenomenon occurs in patients with prosthetic implants and which 
patients are most prone to develop this complication, we analyzed: i) the incidence of the 
development of a PJI in these patients and ii) the clinical characteristics of streptococcal PJI during an 
episode of erysipelas/cellulitis. Based on a retrospective analysis of patients with a prosthetic implant 
in situ presenting at the emergency department with erysipelas/cellulitis, 1 out of 10 patients 
developed a PJI. An additional analysis within a multicenter cohort on streptococcal PJI 
demonstrated in 22 patients that a secondary PJI due to erysipelas/cellulitis mostly develops in young 
implants (<5 years old). In 20 cases (91%), the skin infection was in the same limb as the joint 
prosthesis suggesting contiguous spread of bacteria. These data emphasizes the importance of 
preventive measures to reduce the occurrence of skin infections in patients with prosthetic 
implants, and if an erysipelas or cellulitis does occur, to monitor patients carefully. 
Key words: cellulitis, erysipelas, prosthetic joint infection, contiguous focus, streptococci 
Case Description 
A 60-year old male presented at the emergency 
department with erysipelas of the right lower leg. His 
medical history was unremarkable, with the exception 
that he underwent an uncomplicated primary knee 
arthroplasty on the left side one year before and on 
the right side six months prior to presentation. The 
day before hospital admission, the patient had been 
working on his boat and subsequently developed a 
painful right lower leg, which he interpreted as a 
simple muscle ache. However, the next morning, the 
lower leg started to turn red and he developed a fever 
of 40ºC. He therefore presented to his local hospital 
where a clinical diagnosis of erysipelas and joint 








to the patient, the onset of pain and swelling of the 
knee had developed rapidly over the last couple of 
hours. The other knee was asymptomatic. Because an 
acute prosthetic joint infection (PJI) was suspected, he 
was taken to theatre for surgical debridement, 
exchange of the mobile components of the prosthetic 
joint and pulsed lavage. During surgery, a large 
amount of pus was evacuated, and gentamicin 
impregnated beads were inserted into the joint cavity. 
Intravenous cefuroxime was started after tissue 
samples were obtained. The next day, synovial fluid 
and multiple intraoperative tissue samples came back 
culture-positive for group G beta-hemolytic 
streptococci. Blood cultures that were taken prior to 
the start of antibiotic treatment were negative. After 
two weeks of intravenous antibiotic treatment, the 
patient was switched to oral clindamycin for an 
additional ten weeks of therapy. He made a good 
recovery and remained symptom free during 
five-years of follow-up. 
Introduction 
It has been described that arthroplasty is a risk 
factor for developing erysipelas/cellulitis. Manian et 
al. demonstrated that in the absence of other local 
predisposing factors, the odds to develop an acute 
bacterial skin infection of the ipsilateral extremity 
after primary knee arthroplasty is seven times higher 
compared to the contralateral control limb [1]. This 
higher risk for infection remains for several years after 
the arthroplasty, and is most likely attributed to 
damage to the lymphatic and venous vessels, either 
during surgery or due to postoperative edema or 
hematoma [2-4]. Considering this pathogenesis, it is 
reasonable to assume that the highest risk for a skin 
and/or soft tissue infection is probably in the first 
months after surgery. Indeed, erysipelas/cellulitis is a 
common cause of hospital readmission within 90 days 
after knee arthroplasty, and occurs beyond the 
surgical site [5]. Our case demonstrates a complicated 
course of erysipelas in a patient with a knee prosthesis 
in the same leg, who developed an acute PJI due to a 
Group G beta-hemolytic streptococcus. It is unknown 
how often this phenomenon occurs in patients with 
prosthetic implants and which patients are most 
prone to develop this complication. Osteoarticular 
complications of erysipelas in native joints are rare, 
but have been described [6-9]. As in our case, and as 
depicted in Figure 1, these secondary osteoarticular 
infections tend to be localized to the joint contiguous 
with the skin infection. That the erysipelas was a 
manifestation of the PJI, instead of causing the PJI, is 
highly unlikely in our case, since the erysipelas was 
localized in the lower leg. Considering the fact that 
the incidence of bacteremia in patients with erysipelas 
and cellulitis is very low (5 and 8%, respectively), 
contiguous rather than hematogenous spread is the 
most likely route of infection [10-11]. In the absence of 
bacteremia or a penetrating wound, native joints are 
protected from bacterial invasion by structures like 
synovial membrane and periosteum. However, 
synovial membranes are partly resected during 
primary and revision arthroplasty, which results in a 
disrupted anatomical barrier. In addition, bacteria are 
able to evade the immune system by attaching to 
foreign material and by the formation of biofilm. For 
this reason, it is reasonable to assume that patients 
with a prosthetic joint are more prone to develop a 
secondary infection during an episode of erysipelas or 




Figure 1. Patient with a cellulitis of the right lower leg covering the prosthetic 
joint that was implanted the year prior to presentation. The scar of the primary 
arthroplasty is still visible. Streptococcus dysgalactiae was cultured in multiple 
deep tissue biopsies during surgical debridement. 
 
PJI Secondary to Erysipelas or Cellulitis  
Based on the case presented, we aimed to: i) 
establish the incidence of the development of a PJI in 
patients presenting with erysipelas or cellulitis and ii) 
describe the clinical characteristics of patients who 
develop a PJI after an erysipelas or cellulitis due to 
streptococci.  




Erysipelas or cellulitis with a prosthetic joint in 
situ presenting at the emergency room 
(University Medical Center Groningen, NL) 
To answer the first question, we retrospectively 
evaluated all consecutive patients who presented at 
the emergency department of the University Medical 
Center Groningen (NL) between 2009 and 2016 who 
were diagnosed with erysipelas or cellulitis. Out of 
the 446 cases, ten patients had a prosthetic joint in situ. 
One of these ten patients developed a PJI. It should be 
noted that in general, only severe cases of erysipelas 
and cellulitis are transferred to the emergency 
department (whilst mild cases are treated by the 
general practitioner). It is interesting to note that out 
of the ten cases, only three skin infections were 
located adjacent to the prosthetic joint, including the 
one who developed the PJI. Compared to the six 
month old infected prosthesis, the age of the two 
implants that remained free of infection were five and 
eleven years old, respectively. The remaining seven 
cases had a hip prosthesis, or the prosthesis was 
located at the contralateral side to the skin infection. 
None of these cases developed a secondary PJI. This 
observation supports the concept that patients are at 
highest risk when the skin infection is located close to 
the prosthetic joint. 
Erysipelas or cellulitis with proven 
streptococcal PJI (multi-center analysis) 
To describe the clinical characteristics of patients 
who developed a PJI secondary to an erysipelas or 
cellulitis, we analyzed a cohort of patients taken from 
a large multi-center retrospective study which 
described the clinical outcome of patients with a 
streptococcal PJI treated with debridement, antibiotics 
and implant retention (DAIR) [12]. We selected all 
cases that were marked as having a PJI secondary to a 
contiguous focus. From a total of 36 cases, 17 were 
marked as erysipelas or cellulitis. Participating centers 
provided an additional five cases that were treated 
with revision surgery, resulting in a total inclusion of 
22 cases. Clinical characteristics of the cohort are 
described in Table 1. All of these patients developed 
acute symptoms of a PJI within one week of onset of 
the skin infection. Surprisingly, none of the PJIs were 
caused by S. pyogenes despite this being one of the 
most commonly described cause of erysipelas and 
cellulitis [8]. We cannot fully explain this finding. A 
higher affinity of Group B, C and G streptococci to 
prosthetic implants could be an explanation, which is 
supported by the low incidence (8%) of PJI caused by 
S. pyogenes in the studied cohort (12). These data also 
support the concept of contiguous spread of infection, 
as most of the PJIs developed in knee prostheses 
adjacent to the infected skin. We would like to 
emphasize that the studied cohort were only skin and 
soft tissue infections caused by streptococci, and thus, 
our findings cannot be extrapolated to other 
microorganisms, like Staphylococcus aureus. Compared 
to previous studies describing the incidence of 
bacteremia in skin infections [10-11], the presence of 
bacteremia in our cohort was high (44% of the patients 
in whom blood cultures were obtained [n=9]). 
Although, we cannot exclude the possibility that the 
PJI developed hematogenously in these cases, it is 
most likely that the bacteremia was secondary to the 
PJI. Indeed, in all of the blood culture positive cases, 
the PJI was evident during the initial presentation in 
the hospital. All of the infected implants in our cohort 
were relatively young: 95% were within five years 
after arthroplasty. It has been postulated in the past 
that prosthetic joints are at highest risk for 
hematogenous infection within the first two years 
after implantation, because it takes time before 
anatomical barriers are completely restored and 
therefore, the migration of bacteria to the implant 
might be facilitated during this period. For this 
reason, recommendations concerning antibiotic 
prophylaxis for invasive dental procedures in patients 
who are within the first two years after joint 
placement have been made in the past [14-17]. 
However, because these recommendations were 
mostly advisory and based on expert opinion, newer 
guidelines abandoned this advice [18-19]. The 
relatively young prosthesis’ age in our cohort 
supports the contiguous spread hypothesis 
particularly in young implants. Further studies are 
needed to ultimately conclude on this topic. In 
accordance with our previous data on streptococcal 
PJI [12], the prognosis in our cohort of patients was 
disappointing, with a reported failure rate of 36.4%. 
Conclusion 
Patients with a prosthetic joint in-situ who 
develop erysipelas or cellulitis are at risk of 
developing a secondary PJI, particularly when the 
implant is young and located close to the infected skin 
and soft tissues. Unfortunately, no data is available 
how the development of a PJI in patients with a skin 
infection can be prevented. There is no evidence that 
extending the duration of antibiotic therapy and/or 
increasing the dose of antibiotics provides protection 
for the implant. Our study indicate that providing 
optimal foot care and intensive treatment of chronic 
leg ulcers is of utmost importance in patients with a 
prosthetic implant in situ in order to reduce the 
occurrence of erysipelas or cellulitis. Moreover, when 
patients with a prosthetic joint do develop erysipelas 
or cellulitis, patients should be monitored carefully. 




When a PJI is suspected, extensive surgical 
debridement must be urgently performed [20]. 
 
Table 1. Clinical characteristics of patients who developed a 
streptococcal prosthetic joint infection (PJI) secondary to 
erysipelas or cellulitis. Data are presented as percentages or 
median (IQR). 
Characteristics n = 22 
Joint  
 Knee 86.4% 
 Hip 9.1% 
 Elbow 4.5% 
Type of implant  
 Primary 63.6% 
 Revised 36.4% 
Age of the implant in years 1.5 (0.8 – 3.0) 
 0 – 2 years 57.1% 
 3 – 5 years 33.3% 
 > 5 years 4.6% 
Days between skin infection and onset PJI 3 (1 – 7) 
 Same day 23.8% 
 1 – 5 days 42.9% 
 6 – 10 days 14.2% 
 > 10 days 19.1% 
Skin infection adjacent to the prosthetic joint 91.0% 
Bloodcultures  
 Positive 18.2% 
 Negative 22.8% 
 Not performed 59.0% 
Isolated Streptococcus spp  
 Group B streptococci   
 S. agalactiae 22.7% 
 Not specified 4.5% 
 Group C streptococci   
 S. dysgalactiae  27.3% 
 Not specified 4.5% 
 Group G streptococci   
 Not specified 27.3% 
 Beta hemolytic streptococci not specified 13.6% 
Surgical approach  
 Debridement  71.4% 
 1-stage revision 4.8% 





The authors have declared that no competing 
interest exists. 
References 
1. Manian FA, Kelly E. Lower Extremity Acute Bacterial Skin and Soft Tissue 
Infection Following Total Knee Arthroplasty. Am J Med Sci 2016; 352(2):154-8. 
2. Ebert JR, Joss B, Jardine B et al. Randomized trial investigating the efficacy of 
manual lymphatic drainage to improve early outcome after total knee 
arthroplasty. Arch Phys Med Rehabil. 2013; 94(11):2103-11.  
3. Guyton AC. The lymphatic system, interstitial fluid dynamics, edema and 
pulmonary fluid. Textbook of medical physiology. Philadelphia: Saunders; 
1986: 361-73.  
4. Gao FQ, Li ZJ, Zhang K et al. Risk factors for lower limb swelling after primary 
total knee arthroplasty. Chin Med J (Eng) 2011; 124:3896-9. 
5. Schairer WW1, Vail TP, Bozic KJ. What are the rates and causes of hospital 
readmission after total knee arthroplasty? Clin Orthop Relat Res. 2014; 472(1): 
181-7.  
6. Coste N, Perceau G, Leone J et al. Osteoarticular complications of erysipelas. J 
Am Acad Dermatol 2004; 50: 203-9. 
7. Jorup-Rönström C. Epidemiological, bacteriological and complicating features 
of erysipelas. Scand J Infect Dis 1986;18:519-24. 
8. Eriksson B, Jorup-Rönström C, Karkkonen K et al. Erysipelas: clinicial and 
bacteriologic spectrum and serological aspects. Clin Infect Dis 1996; 23(5): 
1091. 
9. Lanoux P, Penalba C, Legin C et al. L’erysipèle : à propos de 118 observations. 
Med Mal Infect 1993; 23:908-12. 
10. Bauer S, Aubert CE, Richli M et al. Blood cultures in the evaluation of 
uncomplicated cellulitis. Eur J Intern Med 2016; 36: 50-56. 
11. Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis 
and erysipelas. J Infect 2012; 64(2): 148-55. 
12. Lora-Tamayo J, Senneville E, Ribera A et al. The not-so-good prognosis of 
streptococcal periprosthetic joint infection managed by implant retention: the 
results of a large multi-center study. Clin Infect Dis 2017; 64(12):1742-1752. 
13. Stevens DL, Bryant AE. Streptococcus pyogenes: basic biology to clinical 
manifestations. University of Oklahoma Health Sciences Center; 2016. 
14. Curry S, Phillips H. Joint arthroplasty, dental treatment, and antibiotics: a 
review. J Arthroplasty 2002; 17:111–3.  
15. American Dental Association; American Academy of Orthopaedic Surgeons. 
Antibiotic prophylaxis for dental patients with total joint replacements. J Kans 
Dent Assoc 1997; 82(4):14, 16-7. 
16. Uckay I, Pittet D, Bernard L, Lew D, Perrier A, Peter R. Antibiotic prophylaxis 
before invasive dental procedures in patients with arthroplasties of the hip 
and knee. J Bone Joint Surg Br 2008; 90: 833-8.  
17. Rossi M, Zimmerli W, Furrer H et al. Antibiotic prophylaxis for late 
blood-borne infections of joint prostheses. Schweiz Monatsschr Zahnmed 
2005; 115: 571-9.  
18. Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior 
to dental procedures in patients with prosthetic joints: Evidence-based clinical 
practice guideline for dental practitioners--a report of the American Dental 
Association Council on Scientific Affairs. J Am Dent Assoc 2015; 146(1):11-16 
e8. 
19. Sendi P, Uçkay I, Suvà D et al. Antibiotic Prophylaxis During Dental 
Procedures in Patients with Prosthetic Joints. J Bone Jt Infect 2016; 1:42-49.  
20. Urish KL, Bullock AG, Kreger AM et al. A Multicenter Study of Irrigation and 
Debridement in Total Knee Arthroplasty Periprosthetic Joint Infection: 
Treatment Failure Is High. J Arthroplasty. 2017; 17: 31034-3.  
 
 
